Etoperidone was discovered by scientists at
Angelini, who also discovered trazodone.[14] Its development names have included ST-1191 and McN-A-2673-11.[15][1] The
INNTooltip International Nonproprietary Nameetoperidone was proposed in 1976 and recommended in 1977.[16][17] The drug was given brand names in
Spain (Centren (Esteve) and Depraser (Lepori)) and
Italy (Staff (Sigma Tau))[1] and was also given the brand names Axiomin and Etonin,[15] but it is not entirely clear if it was actually marketed; the Pharmaceutical Manufacturing Encyclopedia provides no dates for commercial introduction.[18] According to
Micromedex's Index Nominum: International Drug Directory, etoperidone was indeed previously marketed in Spain and Italy.[1]
Society and culture
Generic names
Etoperidone is the
generic name of the drug and its
INNTooltip International Nonproprietary Name, while etoperidone hydrochloride is its
USANTooltip United States Adopted Name.[15][1][5]
Brand names
Etoperidone has been associated with the brand names Axiomin, Centren, Depraser, Etonin, and Staff.[1][15][18]
Research
Etoperidone has been studied in
dementia and found to be about as effective as
thioridazine.[19]
^Roth BL, Driscol J.
"PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
^
abcdTatsumi M, Groshan K, Blakely RD, Richelson E (1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur. J. Pharmacol. 340 (2–3): 249–58.
doi:
10.1016/s0014-2999(97)01393-9.
PMID9537821.
^
abcdefghiCusack B, Nelson A, Richelson E (1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology. 114 (4): 559–65.
doi:
10.1007/bf02244985.
PMID7855217.
S2CID21236268.
^Stanton T, Bolden-Watson C, Cusack B, Richelson E (1993). "Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics". Biochem. Pharmacol. 45 (11): 2352–4.
doi:
10.1016/0006-2952(93)90211-e.
PMID8100134.
^Raffa RB, Shank RP, Vaught JL (1992). "Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity". Psychopharmacology. 108 (3): 320–326.
doi:
10.1007/BF02245118.
PMID1387963.
S2CID24965789.
^Dörwald FZ, ed. (2012). "46. Arylalkylamines". Lead optimization for medicinal chemists : pharmacokinetic properties of functional groups and organic compounds. Weinheim: Wiley-VCH.
ISBN9783527645640.
^Eison MS, Taylor DB, Riblet LA (1987).
"Atypical Psychotropic Agents". In Williams M, Malick JB (eds.). Drug Discovery and Development. Springer Science & Business Media. p. 390.
ISBN9781461248286.
^Silvestrini B (1986). "Trazodone and the mental pain hypothesis of depression". Neuropsychobiology. 15 (Suppl 1): 2–9.
doi:
10.1159/000118270.
PMID3014372.
Etoperidone was discovered by scientists at
Angelini, who also discovered trazodone.[14] Its development names have included ST-1191 and McN-A-2673-11.[15][1] The
INNTooltip International Nonproprietary Nameetoperidone was proposed in 1976 and recommended in 1977.[16][17] The drug was given brand names in
Spain (Centren (Esteve) and Depraser (Lepori)) and
Italy (Staff (Sigma Tau))[1] and was also given the brand names Axiomin and Etonin,[15] but it is not entirely clear if it was actually marketed; the Pharmaceutical Manufacturing Encyclopedia provides no dates for commercial introduction.[18] According to
Micromedex's Index Nominum: International Drug Directory, etoperidone was indeed previously marketed in Spain and Italy.[1]
Society and culture
Generic names
Etoperidone is the
generic name of the drug and its
INNTooltip International Nonproprietary Name, while etoperidone hydrochloride is its
USANTooltip United States Adopted Name.[15][1][5]
Brand names
Etoperidone has been associated with the brand names Axiomin, Centren, Depraser, Etonin, and Staff.[1][15][18]
Research
Etoperidone has been studied in
dementia and found to be about as effective as
thioridazine.[19]
^Roth BL, Driscol J.
"PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
^
abcdTatsumi M, Groshan K, Blakely RD, Richelson E (1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur. J. Pharmacol. 340 (2–3): 249–58.
doi:
10.1016/s0014-2999(97)01393-9.
PMID9537821.
^
abcdefghiCusack B, Nelson A, Richelson E (1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology. 114 (4): 559–65.
doi:
10.1007/bf02244985.
PMID7855217.
S2CID21236268.
^Stanton T, Bolden-Watson C, Cusack B, Richelson E (1993). "Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics". Biochem. Pharmacol. 45 (11): 2352–4.
doi:
10.1016/0006-2952(93)90211-e.
PMID8100134.
^Raffa RB, Shank RP, Vaught JL (1992). "Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity". Psychopharmacology. 108 (3): 320–326.
doi:
10.1007/BF02245118.
PMID1387963.
S2CID24965789.
^Dörwald FZ, ed. (2012). "46. Arylalkylamines". Lead optimization for medicinal chemists : pharmacokinetic properties of functional groups and organic compounds. Weinheim: Wiley-VCH.
ISBN9783527645640.
^Eison MS, Taylor DB, Riblet LA (1987).
"Atypical Psychotropic Agents". In Williams M, Malick JB (eds.). Drug Discovery and Development. Springer Science & Business Media. p. 390.
ISBN9781461248286.
^Silvestrini B (1986). "Trazodone and the mental pain hypothesis of depression". Neuropsychobiology. 15 (Suppl 1): 2–9.
doi:
10.1159/000118270.
PMID3014372.